An Open-Label, Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis

Trial Profile

An Open-Label, Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis

Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 Jan 2017

At a glance

  • Drugs Imilecleucel-T (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Sponsors Opexa Therapeutics
  • Most Recent Events

    • 25 Apr 2009 Results will be published in the Journal of Clinical Immunology in May 2009.
    • 15 Oct 2008 Planned end date changed from 1 Jun 2008 to 1 Dec 2008 as reported by ClinicalTrials.gov.
    • 23 Jul 2008 Additional data from a pooled extension study have been reported in a media release from Opexa.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top